核心观点 - KEYTRUDA联合LENVIMA对比化疗在晚期子宫内膜癌患者中显示出持久的5年生存获益 [1] 临床试验结果 - 联合疗法在5年生存期方面表现出优于化疗的持久益处 [1] - 该数据针对的是晚期子宫内膜癌患者群体 [1] 产品组合 - 关键产品KEYTRUDA与LENVIMA的联合方案是本次公布的焦点 [1] - 该联合疗法由公司开发 [1]

Presentations at the Congress will feature new or updated findings from Merck's broad portfolio of cancer medicines, including data for KEYTRUDA (pembrolizumab); LENVIMA (lenvatinib), in collaboration with Eisai; WELIREG (belzutifan); and KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa- pmph). Key data being presented on existing medicines in Merck's portfolio: Additionally, new data for investigational antibody-drug conjugates (ADCs) from Merck's innovative pipeline will be presented at the Cong ...